Morrisville expects $12.6 million in tax revenue over eight years but has lowered wage and taxable-value requirements.
By Bhanvi Satija, Oliver Hirt and Marleen Kaesebier LONDON/ZURICH, Sept 11 (Reuters) - Novartis investors are set to step up ...
Shares of Novartis fell more than 3% on Monday after its cholesterol drug failed in a closely watched study, dealing a blow ...
The HARBOR study failure is Novartis's second major late-stage trial setback in days and its third pipeline blow in a week ...
Novartis’ shares fell 13% this week after the report of three separate late-stage asset failures. The impact went beyond the ...
The stock fell about 10% following the announcement and has now lost more than 14% over the past five trading sessions. The failed drug, del-desiran, was being tested against myotonic dystrophy type 1 ...
Novartis AG (NYSE:NVS) has suffered a major setback after its experimental drug del-desiran failed a late-stage trial for myotonic dystrophy type 1, a rare muscle-wasting disease with no approved ...
Back-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit ...
A major shareholder in Novartis has called for a shake-up of the Swiss drugmaker's board to improve corporate governance ...
The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s ...
By Bhanvi Satija, Dave Graham and Marleen Kaesebier ZURICH, Sept 8 (Reuters) - Novartis said on Tuesday its experimental drug for a muscle-wasting disorder failed a late-stage study, the second major ...
Novartis has acknowledged that its neuromuscular candidate delpacibart etedesiran (del-desiran) failed a pivotal Phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results